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1. Introduction 
Chagas disease (CD) or American trypanosomiasis is a complex zoonosis produced by the 
infection with the intracellular protozoan parasite Trypanosoma cruzi. Although the disease 
was first described in 1909 by the Brazilian physician Carlos Chagas, this disease affects 
human beings since antiquity as it was demonstrated by paleoparasitology studies which 
proved the presence of DNA in mummies dating back to 9000 years old (Aufderheide et al., 
2004; Guhl et al., 1999). The parasite T. cruzi is a hemoflagellate protozoan belonging to the 
Mastigophora class, Kinetoplastida order, Trypanosomatidae family, genus Trypanosoma, 
the group Stercoraria. It was named in honor of Oswaldo Cruz, who was the mentor of 
Carlos Chagas. 
T. cruzi has a complex life cycle involving two hosts, an invertebrate, especially an insect 
vector and some vertebrates, including man and domestic and wild reservoirs (Tyler & 
Engman, 2001). The presence of CD in humans is purely accidental, as when the man came 
into contact with natural foci and caused ecological imbalances causing the adaptation of 
vectors to human dwellings and new food sources. Thus three overlapping cycles were 
established: the wild cycle, the peridomestic cycle and the domestic cycle (Coura, 2007). The 
parasite occurs in a variety of hosts and infects 150 species from 24 families of domestic (e.g., 
dogs, cats and guinea pigs) and wild animals (e.g., rodents, marsupials, and armadillos) 
(Rassi, et al., 2010). The vectors involved in the transmission of CD are insects of the Phylum 
Arthropoda, Class Insecta, Order Hemiptera, Family Reduviidae, belonging to the 
subfamily Triatominae. There have been reported approximately 130 species of wild and 
domiciliary triatomines although only a handful is the competent vector for T. cruzi 
(Schofield, 1981). The domestic species mainly colonize rural homes and peri-urban areas 
and these species are responsible for most human cases of Chagas disease in endemic areas. 
Sylvatic species are inhabitants of strict wild habitats such as cracks of rocks, bird nests or 
burrows of mammals and caves, among others. Rhodnius prolixus is the main domestic 
vector in the northern countries of South America and Central America, Triatoma dimidiata in 
Central America and Triatoma infestans in countries of the southern of South America (Guhl, 
2007), these species are well adapted to human habitation.  
T. cruzi presents four different morphological and biological forms: epimastigote, a 
replicative form located in the mid gut of the insect vector, it is the predominant form in the 
axenic culture; metacyclic trypomastigote develops in the posterior intestine and rectum of 
the insect vector and is the infective form; amastigote replicative stage, is located in the 
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cytoplasm of mammalian host cells where it replicates by binary fission; blood 
trypomastigote comes from amastigote differentiation, leading to disruption of the host cell 
and releases into the bloodstream, where they are taken again by the blood-sucking vector 
(Brener, 1971) (Figure 1) 
 
 
Fig. 1. Trypanosoma cruzi different stages. A) Epimastigotes of culture B) Amastigotes in Vero 
cells C) Nests of amastigotes in cardiac tissue D) Blood trypomastigotes stained with 
hematoxiylin-eosin. 
The classic forms of T. cruzi transmission are vectorial, congenital, by transfusion, through 
organ transplants and labour accident. Vector-borne transmission is the most common and 
is contaminative by the presence of the infectious form in the faeces of the vector which is 
released when feeding on the host. The trypomastigotes penetrate through the opening of 
the bite or loss of continuity due to scratching or active penetration of oral or ocular mucosa. 
Before screening programs in blood banks, transfusion was the second form of transmission 
by the presence in donor’s blood or blood products infected with parasite forms (Schmunis, 
1999). Another important source of transmission is the donation of organs from infected 
individuals with the development of acute Chagas in the immunosuppressed recipient 
(Barcan et al., 2005). The passage of the parasite from infected mother to her baby during 
pregnancy, childbirth or while breast-feeding is high in some endemic regions, specially in 
Bolivia. The congenital transmission can lead to abortions, premature births or infected 
babies (Torrico et al., 2004). 
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2. The impact of Chagas disease 
CD is currently is recognized by the World Health Organization (WHO) as one of the 
tropical neglected diseases and the infection with T. cruzi is the third parasitic infection after 
malaria and schistosomiasis (Schmunis & Yadon, 2010). CD is an important public health 
problem in 21 countries of South and Central America. The Pan American Health 
Organization (OPS, 2006) estimates that 7.7 million people are infected with T. cruzi, 109 
million are at risk of infection and 12,500 deaths occur per year. The number of new annual 
cases of vector-borne infection is 41,000 and congenital Chagas' is 14,000 (WHO 2008).  
Although this disease is considered typical of rural areas and poor suburbs with inadequate 
housing conditions, in recent decades in many Latin American countries there has been a 
substantial migration from rural to peri-urban areas. Migration has not only occurred from 
rural to urban areas in Latin America, but also to developed countries of North America, 
Europe and Asia. Accordingly, further cases have been detected in non-endemic countries 
like the USA, Canada, Spain, Japan and Australia due to population migration from 
endemic countries. In the United States have reported more than 300,000 people infected 
with T. cruzi and in Spain from 40 to 60,000 (Bern & Montgomery, 2009; Gascon et al., 2010).  
The migration in endemic countries has led to the passive transport of vectors and the 
emergence of cases in areas considered of low endemicity. Additionally, the national 
initiatives for the elimination of the domestic vectors, including not only insecticide 
spraying but also a rural housing improvement, have led to the elimination of traditional 
vectors. However, a new transmission pattern is being introduced due to the presence of 
palms and trees located close to houses and sylvatic vectors that are attracted sporadically 
by light and feeding conditions. Consequentially, transmission by new vectors has arisen 
and often these vectors often have high rates of infection. This couple with the presence of 
wild reservoirs in the peridomestic area presenting high rates of infection has led to an 
alternate form to vectorial transmission in these areas, such as oral transmission (Briceño-
León, 2009). This form of transmission is usually associated with acute and fatal outcomes 
and it has been increasing especially in the Brazilian Amazon where it is considered an 
emerging disease (Coura et al., 2002). The first report was given in 1960 in Teutonia with 
five deaths involved (Valente et al., 2009). Since then 600 new cases of acute Chagas have 
been reported, 50% associated with oral transmission. There are also reports in Venezuela 
(Alarcon de Noya et al., 2010), Mexico (Salazar-Schettino et al., 2011) and in the last three 
years in Colombia has increased, especially in Santander with six outbreaks of acute Chagas 
and three fatal cases (Díaz et al., 2009).  
3. Clinical aspects of Chagas disease  
3.1 Phases of Chagas disease 
3.1.1 Acute phase 
The clinic course of CD could have two phases: acute and chronic. The acute phase is 
characterized by the presence of T. cruzi trypomastigotes in the bloodstream, the 
parasitaemia generally persists for 4–8 weeks and it resolves spontaneously. In the majority 
of cases, especially in adults, this phase of infection is asymptomatic, however a small 
percentage of patients develops the acute disease characterized by important manifestations 
such as malaise, prolonged high fever, headache, edema, hepatomegaly, splenomegaly and 
generalized lymphadenopathy (Prata, 2001). In the acute form of CD, the first signs appear 
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7–10 days after infection. The Romaña’s sign is observed when the parasite penetrates the 
conjunctiva; but when the parasite penetrates through the skin the patient develops the 
chagoma at the site of inoculation. The adjacent lymph nodes to the site of entry of the 
parasite are generally compromised, which together with the conjunctival or eyelid lesions 
constitute the ophthalmo - lymphonodal complex. Aproximately the fifty percent of the 
patients who develop the acute CD has Romaña’s sign, and one-quarter has the inoculation 
chagoma. The Romaña’s sign is characterized by painless, unilateral swelling of the upper 
and lower eyelid, with rose -violet coloration, congestion and edema of the conjunctiva, the 
submandibular, preauricular or other near lymphonode are enlarged, but not adhering to 
deep layers, occasionally may appear palpebral and periorbital cellulitis, sometimes with 
necrosis and abundant parasites. The inoculation chagoma generally appear on the skin of 
the face or the extremities, and is a forunculoid lesion, with a rose violet tone. In these 
patients, the initial electrocardiogram is normal, but after 2-3 weeks might show anomalies 
such sinus tachycardia, low QRS voltage or first grade atrioventricular block, the chest 
radiograph is also normal, however it might show cardiomegaly (Dias, 1989; Rassi et al., 
2010).   
The majority of patients, (90% or more) with acute CD survive the initial infection and remain 
healthy and asymptomatic, but a few individuals, between 2 -10%, generally infants or 
immunodepressed patients, or many people like children or adults who acquired the infection 
due to oral contamination, develop an acute and severe disease with myocarditis and cardiac 
insufficiency or with meningoencephalitis, clinical conditions that maybe cause death 
(Nobrega et al., 2009). Regarding to the central nervous system (CNS) involvement in CD, in 
the initial acute phase, the infection is asymptomatic and only a small percentage of cases 
develops encephalitis in the acute phase of disease; headache, seizure, focal neurologic signs 
and progressive decrease in consciousness are the notorious symptoms (Cordova et al., 2007). 
3.1.2 Chronic phase 
The great majority of patients, who were infected with T. cruzi, remain asymptomatic in the 
chronic phase, without abnormalities in the electrocardiogram and the radiological 
evaluations of the heart, esophagus and colon. This form of the chronic phase of CD is 
named indeterminate form, it is present in the half of infected people of endemic areas, and 
may persist until dead in 40-50% of the cases. All patients with the indeterminate form of 
CD are positive in serological or parasitological examinations, and do not have symptoms or 
signs of the disease, but using specialized methods such as ambulatory electrocardiographic 
monitoring or endomyocardial biopsies, may demonstrate that they have at least some 
degree of cardiac damage. The morphologic features of the indeterminate form of CD in 
autopsies performed for us in individuals who died of other causes, include discrete focal 
infiltration of mononuclear cells with lymphocytes predominance, and mild interstitial 
fibrosis, these changes are notorious in the subendocardical zone, and near to the cardiac 
conduction system. The change from the indeterminate form to the determinate cardiac or 
digestive occurs slowly in a lapse of 10 – 20 years after the initial infection, in a few cases, 
approximately 2-3% per year. In these patients, the CD adopts a slow and benign course, but 
others develop dilated cardiomyopathy, heart congestive failure or arrhythmias. In sporadic 
cases the CD progresses directly from the acute form to determinate chronic form of human 
CD, and is named the subacute form, that generally affects young adults, these patients 
develop severe cardiopathy with cardiac failure (Marin-Neto et al., 1999).  
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In the chronic phase of CD, the fundamental morphological feature in patients with chronic 
chagasic cardiopathy (CCC) is a mixture of cellular infiltration of lymphocytes and 
monocytes with few plasma cells, and fibrous tissue, that correlate with diverse clinical 
symptoms and signs, since asymptomatic to a congestive syndrome with damage of 
conduction system, arrhythmias, disturbances in the ventricular repolarization and the 
extrasystoles. Thromboembolic phenomens due to cardiac mural thrombosis are also 
frequent. In the majority of these patients, in the thorax radiographs, the heart contour 
appears normal. In some cases the lack of symptoms is surprising, and it does not have 
correlation with damage of tissue detected under microscopical examination. The 
symptomatic patients with CCC related palpitations by arrhythmias or fatigue by cardiac 
failure. In the physical examination, the arrhythmias and the extrasystoles are the most 
frequent clinical features detected. In these patients, the cardiac failure has a slow and 
progressive course, generally with features of right failure predominating the legs edema, 
jugular ingurgitation, ascites, and hepatomegaly. The thromboembolic manifestations due 
to mural thrombosis are frequent, and in autopsies done by us, the pulmonary 
thromboembolism is the most common anatomopathological feature, although brain 
embolism is also recognized in a few cases. After the manifestations of cardiac failure, the 
patients may recover or die in a later episode to one year after the first symptoms of 
decompensation. In these patients the periganglionitis with reduction of neuronal bodies 
especially in the sympathetic system, the sinusal node fibrosis, and destruction of tissues of 
cardiac conduction system and the myocardial cells are related with the early alterations of 
autonomous nervous system. The described changes can explain the reduction of the 
response to cardiovagal reflex in the sinusal node, and the reduction of variability of the 
heart frecuency. The cardiovagal denervation increased the sympathetic tone and could 
explain why the arrhythmias, blockades and sudden death are the first clinical 
manifestations in these patients (Samuel et al., 1983; Rassi et al., 2001). 
The digestive form of CD is present almost exclusively in Argentina, Brazil, Chile and 
Bolivia, although they have reported isolated cases in Colombia, Central America and 
Mexico. The symptoms are the consequence of achalasia. The dysphagia is the first 
disturbance that may lead to malnutrition and weight loss. Odynophagia and epigastric 
pain also occurs in cases of megaesophagus, and chronic constipation, abdominal distension 
and occasionally intestinal obstruction of large bowel in cases of megacolon (Florez et al., 
2010).  
3.2 Pathological anatomy  
The changes described below are the product of the experience gathered in the practice of 
autopsies of patients who died of various forms of CD, and reflect the interaction between 
inflammatory response, cellular damage and alterations of the extracellular matrix, three 
pathologic processes generated by the parasite in the tissues, particularly in the heart, 
esophagus, colon and central nervous system.  
In the acute phase when the infectious forms of T. cruzi penetrate in the cell, such 
macrophages, fibroblasts, Schwann cells, and myocytes, they transform in amastigotes, 
subsequently reproduce and form the parasitic nest or pseudocyst, after 3 – 5 days the 
parasite differentiates to trypomastigote, the pseudocyst enlarges, breaks the cell, releasing 
intact or degenerate forms of the parasite, which act in the interstitium as a particle that 
promotes the inflammatory response. In these cases the heart is enlarged, congestive, flaccid 
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with haemorrhagic foci on the epicardic surface, and at the cut, the cardiac chambers are 
dilated and the myocardium shows areas of haemorrhage and necrosis (Figure 2 A and B). 
In the microscopic examination, the extent of the inflammatory response is proportional to 
the number of pseudocyst and damaged cells. A dense interstitial infiltration of 
lymphocytes, macrophages, with a few neutrophils and eosinophils around the pseudocyst 
and damaged cells is observed in the acute severe form of CD (Figure 2 C and D). 
 
 
Fig. 2. Acute Chagas heart disease A) Heart enlarged with rounded shape. B) The surface of 
cut shows dilatation of four chambers, with pale and red areas, which correspond to focus of 
inflammation, necrosis and haemorrhage C) Nest of Trypanosoma cruzi, dense interstitial 
infiltrate of lymphocytes, plasma cells and monocytes with necrosis of myocardial cells D) 
Nest of Trypanosoma cruzi with rupture of myocardial cell and infiltrate inflammatory of 
mononuclear cells. 
In the chronic phase of CD, the most important feature in chagasic cardiopathy, is the 
enlarge of heart with dilatation of chambers, mural thrombus (Figure 3A) and the mixture of 
cellular infiltration of lymphocytes, monocytes with a few plasma cells, and fibrous tissue 
(Figure 3B). In the adipose tissue of epicardium there are mononuclear cells with 
predominance of lymphocytes, which are more abundant around the nervous fibers and 
ganglionar cells (Figure 3C and 3D).  
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Fig. 3. Chronic Chagas heart disease A) Heart enlarged with dilatation of ventricles and 
mural thrombus B) Separation of the myocardial fibers, edema, abundant fibroblasts whith 
extracellular matrix increase, and scarce mononuclear inflammatory cells. C and D) Marked 
infiltration of lymphocytes and plasma cells around the nervous fibers and ganglionar 
neurons of cardiac plexus.  
In case of oral transmission of the parasite, in the esophagus mucosa there are abundants 
lymphocytes and histiocytes, but the parasites are scarce or not identified (Zafra et al., 2008; 
Mantilla et al., 2010). In the digestive form the CD, the megaesophagus and megacolon are 
the result of destruction of neuronal bodies of intramural autonomic nervous ganglia of 
Meissner and Auerbach of the digestive tube in these sections. 
4. Diagnosis and treatment 
4.1 Laboratory diagnosis 
The diagnosis of T. cruzi infection depends on the phase of infection, in the acute phase the 
patent parasitemia allows the use of parasitological methods to see or culture the parasite in 
A B
C D 
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the first weeks. The diagnosis is difficult in the chronic phase, mainly due the very low or 
intermittent parasitemia, therefore, the serological methods are usual. Additionally, CD 
endemic areas also present endemicity of other parasites especially Leishmania sp. and T. 
rangeli (Gomes et al., 2009). This fact leads to the serological methods which present high 
sensitivity but lack of specificity because of antigenic cross-reactivity. Therefore, the World 
Health Organization recommends that at least two assays based on different techniques 
should be used. The serological methods frequently used in the diagnosis of CD are 
enzyme-linked immunosorbent assays (ELISA), indirect hemagglutination assays (IHA), 
immunofluorescence indirect assays (IFI), immunoblotting assayss (IB), and 
immunochromatographic assay. These methods used crude antigens but recombinant 
proteins and synthetic peptides are being used to improve the specificity (Hernandez et al., 
2010; Praast et al., 2011; Umezawa et al., 2001; Umezawa et al., 2004).   
On the other hand, molecular methods, in particular amplification by the polymerase chain 
reaction (PCR), provide an alternative diagnosis of CD ( Gomes et al., 1999) specially to 
confirm diagnosis in case of inconclusive serology; in addition, it has been performed 
nested-PCR assays (N-PCR) (Marcon et al., 2002), quantitative real-time PCR assays (qRT-
PCR) (Piron et al., 2007) and oligochromatography assays (OligoC) (Deborggraeve et al., 
2009) to improve the detection of T. cruzi DNA.  
4.2 Treatment 
The treatment of CD is aimed at two main aspects: the removal of the parasite and the 
symptomatic management of cardiac manifestations. The options for the treatment of CD 
are restricted to the use of two drugs, the nifurtimox and the benznidazole. These drugs are 
indicated in the acute phase of infection, congenital forms, reactivation associated with 
immunosuppression especially in children and young adults with infections transmitted by 
blood transfusion and organ transplantation. Although the benznidazole have proven to be 
effective in the early stage of chronic infection its effectiveness at the late stage is limited. 
Both drugs produce serious complications such as neurological toxicity, depression, 
anorexia, vomiting and depression in bone marrow. Antitrypanosomal treatment in mild 
and late stage Chagas disease is under study by the BENEFIT trial (Rassi et al., 2010). The 
drug resistance is a major problem in the treatment of infectious and tropical diseases. In CD 
has a strong impact on the increase in the number of therapeutic failure aggravated by the 
few options of treatment, currently, there are numerous efforts in the search for treatment 
alternatives.  
The amioradone is used in the management of cardiac symptoms especially for patients 
with sustained ventricular tachycardia, and for those with non-sustained ventricular 
tachycardia and myocardial dysfunction. Patients haemodynamically unstable, and those 
resuscitated from sudden death are treated with implantable cardioverter defibrillators 
(Rassi et al., 2010). 
5. Pathogenesis and pathophysiology  
The pathogenesis of CD is a process that is not fully understood. Most individuals 
infected with T. cruzi do not develop an acute phase and the injury to the myocardium 
and nervous system is directly related to tissue parasitism. The rupture of the nests of 
parasites in the tissues releases antigens of T. cruzi sensitizing cardiac and neuronal fibers, 
www.intechopen.com
 Chagas Heart Disease 
 
757 
leading to the destruction of these cells by anti-T. cruzi response mediates by CD8+ and 
CD4+ lymphocytes (Palomino et al., 2000). For the chronic phase, different mechanisms 
have been proposed; it is currently accepted that the inflammatory response generated by 
the parasite, which has not been eliminated by the immune system induces chronic 
inflammation in some individuals leading to tissue damage (Tarleton, 2003). There are 
several factors that directly or indirectly contribute to the progression and therefore 
evolution of the CD in the host. Some of these factors are inherent to the parasite, as the 
virulence related to their tissue tropism, their genetic and antigenic features, others are 
related to the host, such as age, race, nutritional status, immune response and genetic 
constitution (Dutra & Gollob 2008). 
5.1 Associated to T. cruzi 
T. cruzi presents a great heterogeneity both genotypic and phenotypic (Tibayrenc et al., 
1993) and consists of different populations which circulate among humans, vectors, 
domestic animals and wild reservoirs. These populations show different behaviors in terms 
of parasitaemia, virulence, pathogenicity, interactions with host cells, tissue tropism and 
sensitivity to drugs. T. cruzi has been classified into several groups, initially using 
biochemical markers (zymodemes) and subsequently molecular markers (esquizodemes, 
clonets and lineages). The last meeting of experts standardized the nomenclature of T. cruzi 
and accepted the existence of six discrete typing units (DTUs) called TCI-VI (Zingales et al., 
2009). The heterogeneity of T. cruzi extends to the forms and severity of clinical presentation 
with a particular geographical distribution. In Brazil, Tc I is present in the sylvatic cycle of 
transmission with low parasitemia in humans and experimental animals, therefore it is 
considered non-virulent, except for some reports of the Amazon (Texeira et al., 2006). By 
contrast, in this country Tc II is involved in the domestic cycle of transmission and causes 
high parasitemias, human infections and both heart and gastrointestinal diseases (Zingales 
et al., 1998). The same behavior is observed in other southern countries of South America as 
Argentina, Chile, Paraguay and Uruguay. By contrast, in the northern countries of South 
America and Central America predominates Tc I associated with heart disease and involved 
in both domestic and sylvatic cycle (Higo et al., 2004). Recently, our group reported the 
presence for both groups for the first time, Tc I and Tc II group in blood of seropositive 
individuals to antigens of T. cruzi associated with chagasic cardiomyopathy (CC) (Zafra et 
al., 2008, Gonzalez et al., 2010). The two groups were also identified in tissues of deceased 
patients with CC, with predominance of Tc I (Zafra et al., 2011). One individual presented a 
mixed infection with Tc I and Tc II, but Tc II was the group associated with cardiac 
involvement (Mantilla et al., 2009). 
5.2 Associated with the host 
5.2.1 Innate immune response 
In recent years, new data related with interaction between innate immune cells and T. cruzi 
have been presented. This interaction is crucial in controlling parasite replication and 
removal by the action of phagocytic cells, activation of antigen presenting cells and natural 
killer cells (NK) in the host tissue. The innate immune cells recognize pathogen associated 
molecular patterns (PAMPs) through their pattern recognition receptors (PRR). The best 
characterized PRRs are Toll-like receptors (TLRs), which are expressed in the cell membrane 
or are located intracellularly. When TLRs recognize microbial components, it induces 
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signals responsible for the activation and production of inflammatory cytokines and 
chemokines (Akira & Takeda, 2004). In T. cruzi, TLR2 was the first receptor identified which 
recognizes glycosylphosphatidylinositol (GPI)-anchores mucin-like glycoproteins, 
distributed to the cell surface membrane of T. cruzi trypomastigotes (Campos et al., 2001). 
This receptor also recognizes the T. cruzi protein Tc52 and induces dendritic cell activation 
(Ouaissi et al., 2002). The TLR4-MD2 complex recognizes glycoinositolphospholipids 
containig ceramide (GIPL) (Bafica et al., 2006) and TLR9 recognizes DNA rich in CpG 
sequences. The TLR-mediated MyD88 signaling pathway induces pro-inflammatory 
cytokines as TNF-α and IL-12 and stimulates the production of nitric oxide (NO) involved in 
parasite clearance (Bafica et al., 2006). Other mechanisms for the TLR- independent 
recognition of T. cruzi have been described and involved the molecule NOD1 that induces 
type I IFNs (Kayama & Takeda, 2010). Innate immunity in turn acts as an 
immunomodulatory specific immune response through the generation of the 
microenvironment of cytokines that regulates the differentiation of effector T cell 
subpopulations (Bilate & Cunha-Neto, 2008, Dutra et al., 2009). 
5.2.2 Adaptative immune response 
The role of the adaptative immune response in the pathogenesis of CD has been subject of 
much controversy, for decades the role of the autoimmune component was accepted as 
directly responsible for heart damage (Takle & Hudson, 1989). This was supported by the 
detection of autoantibodies against cardiac antigens, chronicity and difficulty of finding 
parasites in affected individuals (Cunha-Neto et al., 1995). However, the development of 
more sensitive molecular tests that allowed detection of low numbers of parasites, the fact 
that immunosuppressed patients developed acute and severe CD and experimental models 
showed that the parasite, even in small amounts was essential for the development of the 
disease (Zhang & Tarleton, 1999; Tarleton, 2003). The presence of autoantibodies may be 
explained by the release of autoantigens as the result of the immune response against the 
parasite (Cunha-Neto et al., 1995).  
Currently, the role of chronic inflammation and unbalance of the immune response 
generated by the parasite is accepted as responsible for the damage and tissue regeneration 
associated with organ dysfunction (Dutra & Gollob 2008). Although heart inflammatory 
cells contribute to control parasite growth, they are also involved in perpetuating 
inflammatory infiltrate. In chagasic patients the cellular infiltrate consists mainly of T 
lymphocytes with a predominance of CD8+ cells but also contains CD4+ cells and 
macrophages. Both CD8+ cell and CD4+ exhibit characteristics of activated T cells and 
correlate with the expression of inflammatory cytokines such as TNF-α and INF-γ and a 
smaller number of regulatory cells producing IL-10 (Araújo et al., 2007). Patients with 
chronic CC have higher serum levels of TNF-α and CCL2 compared with asymptomatic 
individuals (Talvani et al., 2004). In this context, cytokines, chemokines, receptors and 
signaling pathways associated with activation of pro-inflammatory proteins and with low 
expression of immunoregulatory proteins will be clearly associated with the 
immunopathogenesis of CD. This coupled with the fact that most infected individuals 
remain asymptomatic throughout life and only between 15 to 30% of them developed the 
disease demonstrates the importance of host genetic component. Thus individuals with 
genetic predisposition to proinflammatory phenotype in the presence of T. cruzi would be 
those that develop chronic and severe forms of the disease. 
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6. Chagas disease as a complex disease 
6.1 Human genome variation 
The variation in the human genome sequence plays an important role, yet little known in 
the etiology of many diseases. The establishment of the association between genotype and 
phenotype is crucial for understanding biological processes and in the case of disease, 
pathogenic mechanisms that lead to their development. For monogenic diseases, the 
methods of genetic linkage and physical maps facilitated the identification of mutations 
responsible for the phenotype associated with pathology. Thus numerous Mendelian-type 
diseases were identified. However, most common diseases are complex and multifactorials 
therefore, are the result of the effect of multiple genetic variants on the phenotype and their 
interaction with environmental factors. In the case of infectious diseases is known that not 
only the genotypic and phenotypic differences of the microorganism determine the 
development of a particular disease, but also the variation in the host genome may have an 
important role in the development of resistance or susceptibility.  
6.2 Single nucleotide polymorphisms (SNP) 
SNP type polymorphisms are the most common forms of genetic variation in the human 
genome, currently the common SNPs estimated density is about 10 to 15 million (The 
International HapMap Consortium 2007, http://www.hapmap.org). Its usefulness as genetic 
markers associated with various infectious and noninfectious diseases has been amply 
demonstrated (Pacheco & Moraes, 2009). The SNPs have been the markers most commonly 
used for its stability, low mutation rate and are plentiful throughout the genome, being found in 
exons affecting the protein function, in introns or regulatory regions affecting gene expression 
and therefore the processing and maturation of the messenger, or many of them have been 
identified in intergenic regions with effect unknown over gene expression or phenotype (Frazer 
et al., 2009). Numerous reports using one or more polymorphisms have been published 
(Pacheco & Moraes, 2009), but most of them only explain less than 5% of the observed 
contribution of the genetic component to the risk of disease. This fact substantially limits the use 
of these markers to predict risk and in some cases the results have been controversial. One of 
the main problems with these studies is that in many cases it is not known a direct effect on the 
phenotype and in common diseases the effect is modest. Therefore, it is necessary to identify 
other variables involved and the interaction among them (Feero et al., 2010). Another limitation 
in this type of study is related to the number of SNPs, which in an individual genome is from 3 
to 4 million and in the human genome it is estimated between 10 to 11 million (Frazer et al., 
2009). Thus an individual would require testing thousands of polymorphisms to identify genes 
involved in susceptibility to a particular pathology.  
The International HapMap Project (The International HapMap Consortium 2003-2007) has 
overcome some of the difficulties in mapping SNPs and identification of susceptibility genes in 
complex diseases. The advances are related with the reduction in the number of SNPs to be 
genotyped, increased statistical power and the accurate mapping in association studies. This 
project HapMap anticipates building a database for common haplotypes in different human 
populations (www.hapmap.org). When the markers are in linkage disequilibrium (LD) in the 
population, there is redundant information. If two markers are in complete LD, each of the 
genotypes of a SNP is completely determined by the other, thus the genotyping of one will 
suffice for the information of the two (Conrad et al., 2006). The selection of non-redundant 
markers present in an area with high density of markers has been called "haplotype tagging" 
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and the SNPs selected by this method are called "tag-SNPs" or label SNP (de Baker et al., 2006). 
The main objective of this haplotype tagging is to reduce the number and cost of genotyping, 
keeping most of the information that they contain (Daly et al., 2001). The technological 
progress in the last decade, related to the development of high density maps of markers, maps 
of linkage disequilibrium and haplotypes (Cardon & Abecasis, 2003), the use of microarrays 
for genotyping of SNPs (Steemers & Gunderson, 2007) and bioinformatics tools have helped 
overcome some of these difficulties. Based on these developments, in recent years the genome 
scans (GWAS) have popularized (Cheung et al., 2005; Galvan et al., 2010). In fact, after 5 years 
of the first GWAS, which identified the association of complement factor H with macular 
degeneration related to age (Klein et al., 2005) there have been published more than 450 GWAS 
and associations with more than 2000 SNPs in numerous human diseases such as type 1 and 2 
diabetes, Crohn's disease, rheumatoid arthritis, prostate cancer, breast, tuberculosis and 
visceral leishmaniasis among many others (Manolio 2010; Ku et al., 2010). Many of these 
studies have identified markers on genes already known for its role in the pathogenesis of the 
disease, but others have also identified strong associations with genes that apparently have not 
relation with the characteristic of the disease process (Frazer et al., 2009). 
6.3 Human genome variation in Chagas disease 
The chronic CD courses in 70% of individuals without symptoms and only between 15-30% 
of infected individuals have cardiac involvement and/or digestive, with different levels of 
severity and mortality. This clearly suggests the role of the individual genetic component in 
disease development, a fact that is reinforced with the identification of strains of mice with 
different susceptibility phenotypes. The C3H strain develops cardiac lesions similar to 
human chagasic cardiomyopathy, the A/J phenotype presents different pathology and 
DBA/2 is totally resistant (Marinho et al., 2004). The association related with genetic 
susceptibility or resistance to infection with T. cruzi in human has been demonstrated in 
some epidemiological studies related to the molecules of the major histocompatibility 
complex (MHC) (Llop et al., 1991; Fernández-Mestre et al., 1998; Nieto et al., 2000; Layrisse 
et al., 2000; Williams-Blangero et al., 2003; Moreno et al., 2004).  
The identification of biomarkers to establish an association with the risk of developing the 
disease is critical because could be used not only in prevention and prognosis but also as a 
therapeutic target. It is now clearly accepted that the immune response is crucial in the 
pathogenesis of CD and especially the role of the chronic inflammation in the tissular damage 
(Dutra & Gollob 2008). The balance between anti-inflammatory and pro-inflammatory 
cytokines and their receptors is crucial in determining whether T. cruzi parasites will be 
eliminated without causing tissue damage. Thus, the lack of efficient immunoregulation in 
cardiomyopathic patients could contribute to clinical forms of CD. In this sense, case-control 
studies have searched association between onset or severity of the disease and the functional 
polymorphisms of genes known to participate in host inflammatory response.  
6.3.1 Variation in pro-inflamatory cytokines 
In CD, it has been observed that patients infected with T. cruzi display increased levels of 
plasma TNF-α compared to non-infected individuals, where plasma TNF-α levels were 4-
fold higher in asymptomatic and cardiomyopathic patients with left ventricular ejection 
fraction (LVEF) >50% and 8-fold higher cardiomyopathic patients with LVEF ≤50% than 
non-infected individuals (Ferreira et al., 2003). In fact, the measurement of TNF-α level has 
been suggested as a tool to identify patients with heart dysfunction (Talvani et al., 2004).  
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Some positive associations have been observed in Mexican and Brazilian populations, 
between polymorphisms of regulatory region of TNFA gene and CC (Rodríguez-Pérez et al., 
2005; Drigo et al., 2006; Pissetti et al., 2011). The most studied allelic form (TNFA -308) has 
functional implication because it affects the TNF-α level. However, discrepancies have been 
observed with Peruvian and Brazilian populations in which the frequencies of genetic 
variants were similar in asymptomatic individuals and CC patients (Beraún et al., 1998; 
Drigo et al., 2007). These differences could be affected by some factors. Among the most 
important factors would be: sample size, genetic differences between populations, criteria 
for the selection of controls (study design), linkage disequilibrium with HLA genes and 
influence of other polymorphisms present in the same region. Some polymorphisms of 
TNFA gene show a high level of LD, and the haplotypes formed by these variants could be 
affecting levels of protein expression (Figure 4). In Colombian population of highly endemic 
area we also found associations with genetic variants in TNFA and TNFR2 genes (Criado et 
al., publication process). Unlike other chronic inflammatory diseases such as rheumatoid 
arthritis in which the blocking of TNF-α has been used successfully in treatment, in CD the 
experimental evidence using animal models showed that TNF-α blockade enhances left 
ventricular dysfunction (Bilate et al., 2007). Therefore, it is necessary to understand the 
regulation of the expression of TNF-α and its receptors and the effect of host 
polymorphisms for the use of therapeutic strategies with target TNF-α.  
 
 
Fig. 4. Plot of LD across the TNFA gene. The image shows a high-resolution LD association plot 
between SNPs located in the TNFA gene, D’ values are reported in the boxes and represented 
by color, which ranges from red (higher D’ scores) to white (lower D’ scores). The SNP 
nomenclature is presented as numbers that refer to the position of polymorphism in the gene. 
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In our study population we also found associations of functional polymorphisms present in 
other pro-inflammatory cytokine genes such as IL1B (Flórez et al., 2006), IL12B (Zafra et al., 
2007), IFNG (Torres et al., 2010), and lack of association with IL6 (Torres et al., 2010) (Table 
1).  
6.3.2 Variation in chemokines and chemokine receptors 
The inflammatory infiltrate of mononuclear cell is driven by a set of specific chemokines 
that determine the type of cells present in the tissue. Chemokines and chemokine 
receptors play an important role in mediating the extravasation and accumulation of 
specific effector and memory cells in chronic inflammatory processes in several diseases. 
In CD there is experimental evidence in patients with CC and models of T. cruzi infection 
that show that chemokines and chemokine receptors may be relevant mediators of 
leukocyte influx, which is involved in the pathogenesis of the disease (Teixeira et al., 2002; 
Marino et al., 2004; Talvani et al., 2004; Machado et al., 2005; Gomes et al., 2005; Guedes et 
al., 2010; Manque et al., 2011). Genetic variants in genes of chemokine receptors as CCR5 
have been also studied in Peruvian and Venezuelan populations with the identification of 
a protection marker (Calzada et al., 2001; Fernandez-Mestre et al., 2004). CCR5 gene 
polymorphisms had been extensively studied in HIV and have been defined haplogroups 
which are affecting the transcriptional activity (Gonzalez et al., 1999). These haplogroups 
are composed by different combinations of CCR2 and CCR5 SNPs (Figure 5). Analyzing 
individual polymorphisms we found association between CCR5-2733 polymorphism and 
CC and also in four variants present in haplogroup HHE (CCR2 +190, CCR5 -2733, -2554 
and -1835).  
 
 
 
 
 
Fig. 5. Human haplogroups of CCR2 and CCR5 polymorphisms. 
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No association was observed with polymorphisms analysed in the chemokines CCL5 and 
CXCL8 genes (Flórez et al., publication process). The genetic variant – 2518 in the chemokine 
CCL2/MCPI promotor gene was associated with CC in Brazilian population (Ramasawmy et 
al., 2009). 
6.3.3 Variation in anti-inflammatory cytokines  
Monocytes of patients with the indeterminate form, but not patients with CC showed high 
expression of interleukin 10, suggesting a lack of immunoregulation in these patients 
(Costa el al., 2009; D'Avila et al., 2009). The anti-inflammatory cytokines, such as 
interleukin 4 and IL-10, promote Th2 differentiation and limit Th1 response (Jankovic et 
al., 2001). This polarization favors the permanence of the parasite in the myocardium but 
keeps the inflammatory response under control, which appears to be important for 
avoiding the development of CC (Higuchi et al., 2003; Cunha-Neto et al., 2005). Different 
groups have found markers associated with decreased production of anti-inflammatory 
cytokines in patients with CC (Costa et al., 2009). We have analyzed other genes of 
regulatory proteins, such as TGFB1 (Calzada et al., 2009), MIF (Torres et al., 2009), IL4, 
IL4RA and IL10 (Florez et al., 2011) which are associatted with CC. However, in the latter 
gene we were unable to demonstrate association between IL10 gene polymorphism and 
CD. Other pro-inflammatory and anti-inflammatory genes have been analyzed, such as 
BAT1 and IKBL/NFKBIL1, MAL/TIRAP (Ramasawmy et al., 2006 and 2009), PTPN22 
(Robledo et al., 2007), CTLA4 (Fernandez-Mestre et al, 2009) (Table 1). 
There are few reports of genome mapping applied to the study of CD in murine models 
which showed a possible region of susceptibility to the disease directly related with 
survival to infection in the murine H-2 locus, which corresponds to the human Major 
Histocompatibility Complex (MHC) located in chromosome 17 (Wrightsman et al., 1984). 
In a more recent study, the entire genome of mice strains susceptible and resistant were 
mapping at intervals of 10-15 cM with microsatellite. The regions with marked influence 
in the severity of CD, are mainly located on chromosome 17 on the murine MHC, but 
were also identified as candidate regions on chromosomes 5 and 13 (Graefe et al., 2003, 
2006). In humans, chromosomal mapping studies on CD have not been reported. All this 
evidence showing the association of multiple genes and the development of CD, as in 
other infectious and noninfectious diseases, suggests that susceptibility/resistance to 
develop CD would be determined by variations in a large number of polymorphic genes. 
In fact, a single SNP can not fully explain the susceptibility or resistance to a complex 
disease. Therefore, the genetic susceptibility to T. cruzi infection and the development of 
cardiomyopathy is complex and heterogeneous and likely to involve multiple genes, each 
with a modest contribution on the pathogenesis of the disease. The availability of high 
throughput methods enabling of genotyping individual DNA samples at 500,000 or more 
loci using SNP chip have led to genome wide association studies (GWAS) of more than 40 
diseases and human phenotypes (Manolio, 2010). Despite the current limitations and the 
adjustments of bioinformatic tools for analyzing this vast amount of information, these 
studies of genomic medicine would allow in a near future obtain the individual genetic 
profiles and define the genes underlying the phenotype associated with the disease and 
its severity.  
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Genes SNP Population Association Reference 
Innate immunity    
TLR 2 R753Q Colombian negative Zafra 
TLR4, TLR9 D299G, -1237 Colombian negative Zafra 
TLR 1,2,4,9 
I602S, R753Q, D299G, R392stop 
codon, -1237, -1486 
Brazilian negative Ramasawmy 
MAL/TIRAP S180L Brazilian CC Ramasawmy 
Pro-inflamatory genes    
NOS microsatélite Peruvian negative Calzada 
NRAMP -236 Peruvian negative Calzada 
TNFA -308 Peruvian negative Beraún 
  Mexican CC Rodriguez-Pérez 
  Brazilian negative Drigo 
  Brazilian negative Pissetti 
  Colombian CC Criado 
 -238 Peruvian negative Beraún 
  Mexican negative Rodriguez-Pérez 
  Brazilian negative Drigo 
  Brazilian CC Pissetti 
 -1031 Colombian negative Criado 
TNFR2 +676 (M196R) Colombian monomorphic Criado 
LTA +80, +252 Brazilian  Ramasawmy 
IL1B +5810 Colombian CC Flórez 
 -31,-511, +3954 Colombian negative Flórez 
  Mexican  Cruz-Robles 
IL1RN +8006, +8061, +11100 Colombian negative Flórez 
  Mexican  Cruz-Robles 
IL1A -889, +4845 Colombian negative Flórez 
IL12B +1188 Colombian CC Zafra 
IFGN +874 Colombian CC Torres 
IL6 -174 
Colombian, 
Peruvian 
negative Torres 
CCR5 59029, Δ32 Peruvian negative Calzada 
 59029, Δ32 Venezuelan negative Fernández-Mestre 
 -2733, -2554 Colombian CC Flórez 
CCL2/MCPI -2518 Brazilian CC Ramasawmy 
Anti-inflamatory genes    
BAT1 -22, 348 Brazilian CC Ramasawmy 
IKBL/NFKBIL1 -62, -262 Brazilian CC Ramasawmy 
IL10 -1082 Brazilian CC Costa 
 -1082, -819, -592 Colombian negative Flórez 
PTPN22 1858 
Colombian, 
Peruvian 
negative Robledo 
MIF -173 
Colombian, 
Peruvian 
CC Torres 
TGFB -988, -800, -509, +263 
Colombian, 
Peruvian 
negative Torres 
 +10 
Colombian, 
Peruvian 
CC Torres 
CTLA4 +49 Venezuelan negative Fernández-Mestre 
IL4 -590 Colombian negative Flórez 
IL4RA +148 Colombian CC Flórez 
 1124, 1218, 1902 Colombian negative Flórez 
Table 1. Polymorphisms of immune response genes studied in Chagas Disease 
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6.4 Host-parasite interaction, changes in gene expression by the infectious process 
The infection process involves changes in host cell gene expression caused by the 
parasite. Therefore, transcriptional profiling is frequently used as a genome-wide tool to 
screen for the impact of pathogens on host cell functions (Costales et al., 2009). This 
approach that analyzes the differential expression to identify genes or proteins related 
with the pathogenesis is widely used in different pathologies. Taking advantages of 
microarray expression platform comparisons are made between healthy and sick 
individuals or between strains of susceptible or resistant animal models or between 
infected and uninfected cells. Currently, two approachs have been integrated so that data 
from microarrays can be analyzed in the context of the Quantitative Trait Loci (QTLs), a 
strategy called genetic genomics (Jansen & Nap 2001; Nica et al., 2010). Genetics 
Genomics is a powerful tool to elucidate the basis of complex traits and disease 
susceptibility that integrates genotype and phenotype information (Pérez-Enciso et al., 
2007).  
In CD studies using different cell lines infected with T. cruzi or tissues from diseased 
individuals compared to healthy tissue have been realized. This allowed to identify an 
increased number of over-expressed genes associated with immune response, such as 
growth factors, immunoglobulins, cytokines and genes related with cell membrane, lipid 
metabolism and oxidative phosphorylation (Graefe et al., 2006; Mukherjee et al., 2003; 
Mukherjee et al., 2006). More recently in several human cell lines was observed 
overexpression of cytokines with higher overexpression of interferon-stimulated genes and 
also independent genes of cytokines (Costales, 2009). An analysis of gene expression in heart 
tissue of five patients with CC and seven with dilated cardiomyopathy suggests that genes 
of immune response, lipid metabolism and mitochondrial oxidative phosphorylation could 
be involved in the development of heart failure (Cunha-Neto, 2005). In mice models, 
myocarditis was associated with immune-inflammatory responses (chemokines, adhesion 
molecules, cathepsins, and MHC molecules), and fibrosis was associated with extracellular 
matrix components, lysyl oxidase, and tissue inhibitor of metalloproteinase (Soares et al., 
2010). With this approach, our group performed a study for determining differential 
expression patterns in T lymphocytes of individuals with or without CC. Using the Gen 
Ontology (GO) tool we could establish the biological pathways associated with over-
expression in immune response genes, cell signaling and structure of cardiac tissue. 
Therefore, genetic genomic strategy could allow establish and identify the risk genotype and 
phenotype of the patient. In addition would make it possible to identify gene interaction 
networks responsible for the development of CD.  
7. Perspectives 
For the control of CD should be used not only the traditional approachs of public health 
with campaigns to eradicate the domiciled vector, control of transmission in blood banks, 
and now oral transmission, but implement and promote the use of new developments in 
genomics, proteomics and pharmacogenomics. The association studies and genetic genomic 
can provide information to identify genes related with disease development and so develop 
not only prevention and control programs but identify potential targets for treatment and 
vaccine design.  
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